BSX Boston Scientific Corporation - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
BSX Stock | Fundamental Analysis & Investment Insights
NYSE
Healthcare
Medical Devices
Current Price
Live
$92.51
Analyst Target
$124.41
+34.5%
Upside
52W High
$109.5
52W Low
$85.98
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$137.19B
P/E
48.69
ROE
12.5%
Profit margin
14.4%
Debt/Equity
0.51
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
72%
Analysis Accuracy
Boston Scientific (BSX) shows mixed signals with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limits distress risk assessment. Despite strong revenue and earnings growth, elevated valuation metrics (P/E of 48.69 vs sector avg 199.90) and bearish insider activity offset positive momentum. The stock trades well above its Graham Number of $25.97 and even the growth-based intrinsic value of $56.05, reflecting high market expectations. While analyst consensus is strong_buy with a $124.41 target, weak technical trend and insider selling raise caution.
Key Strengths
Strong year-over-year revenue growth of 20.30% and earnings growth of 60.00% demonstrate robust top- and bottom-line expansion.
High gross margin of 68.33% reflects pricing power and efficient manufacturing in the medical devices space.
Consistent earnings beat streak: 3 out of last 4 quarters beat estimates with an average surprise of 6.68%.
Solid return metrics: ROE of 12.49% and ROA of 5.76% indicate effective capital utilization.
Low debt/equity ratio of 0.51 suggests conservative leverage and strong balance sheet flexibility.
Key Risks
Weak Piotroski F-Score of 4/9 signals potential financial instability, particularly in profitability and leverage trends.
Current price of $92.51 is significantly above both Graham Number ($25.97) and intrinsic value ($56.05), implying overvaluation risk.
Bearish insider sentiment: 9 sell transactions totaling $26.85M in the last 6 months with no buys, suggesting lack of confidence from insiders.
Technical trend score of 0/100 indicates deteriorating price momentum, supported by negative 1Y (-9.0%) and 6M (-12.8%) returns.
Quick ratio of 0.77 is below 1.0, indicating potential short-term liquidity pressure despite a current ratio of 1.51.
AI Fair Value Estimate
Based on comprehensive analysis
$58.5
-36.8% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
44
Moderate
35
75
60
42
10
AI Verdict
Neutral with upside risk if growth sustains
Key drivers: High growth metrics, Elevated valuation, Weak Piotroski score, Bearish insider activity, Strong analyst target upside
Confidence
75%
Value
35/100
Ref P/E, PEG, Graham Number
Positives
- Lower P/E than sector average (48.69 vs 199.90)
- Forward P/E improves to 26.65
Watchpoints
- Current price ($92.51) is 58% above intrinsic value ($56.05)
- Price is 254% above Graham Number ($25.97)
- High P/B (5.86) and P/S (7.09) relative to historical norms
Future
75/100
Ref Growth rates
Positives
- YoY revenue growth of 20.30%
- YoY earnings growth of 60.00%
- Q/Q earnings growth of 61.00%
- Analyst target implies 34.5% upside to $124.41
Watchpoints
- PEG Ratio unavailable – uncertainty in growth sustainability
- Forward P/E still elevated at 26.65
Past
60/100
Ref Historical trends
Positives
- 20 of last 25 quarters beat EPS estimates
- 5-year price return of +151.5% outperforms market
- Consistent margin expansion and profitability
Watchpoints
- Recent Q/Q EPS growth flat at 0.0%
- Two negative earnings surprises in last 5 quarters
Health
42/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Debt/Equity of 0.51 is below sector average (2.68)
- Current ratio of 1.51 indicates adequate short-term coverage
Watchpoints
- Piotroski F-Score of 4/9 is in 'stable' range but close to weak threshold
- Quick ratio of 0.77 < 1.0 signals inventory-heavy liquidity risk
- No Altman Z-Score available – missing key distress indicator
Dividend
10/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength: 0/100
- No dividend yield or payout history
- Payout ratio is 0.00% – no return to shareholders
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$92.51
Analyst Target
$124.41
Upside/Downside
+34.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BSX and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BSX
Boston Scientific Corporation
Primary
|
+151.5% | +101.8% | -9.0% | -12.8% | -3.8% | +5.0% |
|
SYK
Stryker Corporation
Peer
|
+58.2% | +46.1% | -3.8% | -6.1% | +3.4% | -1.0% |
|
PFE
Pfizer Inc.
Peer
|
-10.9% | -33.8% | +3.8% | +8.5% | +2.4% | +0.7% |
|
GILD
Gilead Sciences, Inc.
Peer
|
+125.7% | +62.5% | +40.1% | +17.0% | +2.9% | +3.1% |
|
VRTX
Vertex Pharmaceuticals Incorporated
Peer
|
+90.3% | +41.5% | +5.8% | -4.0% | -1.8% | -4.8% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
48.69
Forward P/E
26.65
PEG Ratio
N/A
P/B Ratio
5.86
P/S Ratio
7.09
EV/Revenue
7.66
EV/EBITDA
29.21
Market Cap
$137.19B
Profitability
Profit margins and return metrics
Profit Margin
14.43%
Operating Margin
20.73%
Gross Margin
68.33%
ROE
12.49%
ROA
5.76%
Growth
Revenue and earnings growth rates
Revenue Growth
+20.3%
Earnings Growth
+60.0%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+61.0%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.51
Moderate
Current Ratio
1.51
Good
Quick Ratio
0.77
Poor
Cash/Share
$0.86
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-04
$N/A
2025-10-22
$0.75
+5.1% surprise
2025-07-23
$0.75
+3.4% surprise
2025-04-23
$0.75
+11.5% surprise
Healthcare Sector Comparison
Comparing BSX against 147 companies in the Healthcare sector
(11 bullish, 53 neutral, 83 bearish)
P/E Ratio
48.69
This Stock
vs
164.49
Sector Avg
-70.4%
(Discount)
Return on Equity (ROE)
12.49%
This Stock
vs
-52.77%
Sector Avg
-123.7%
(Below Avg)
Profit Margin
14.43%
This Stock
vs
-20.75%
Sector Avg
-169.6%
(Weaker)
Debt to Equity
0.51
This Stock
vs
6.16
Sector Avg
-91.7%
(Less Debt)
Revenue Growth
20.3%
This Stock
vs
135.79%
Sector Avg
-85.1%
(Slower)
Current Ratio
1.51
This Stock
vs
3.36
Sector Avg
-55.1%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BSX
Boston Scientific Corporation
|
NEUTRAL | $137.19B | 48.69 | 12.5% | 14.4% | $92.51 | |
|
SYK
Stryker Corporation
|
BEARISH | $139.12B | 47.8 | 14.0% | 12.1% | $363.78 | |
|
PFE
Pfizer Inc.
|
NEUTRAL | $145.84B | 14.91 | 10.6% | 15.7% | $25.65 | |
|
GILD
Gilead Sciences, Inc.
|
NEUTRAL | $154.99B | 19.34 | 40.7% | 27.9% | $124.91 | |
|
VRTX
Vertex Pharmaceuticals Incorporated
|
NEUTRAL | $113.16B | 31.04 | 22.3% | 31.3% | $441.36 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-01 | BUTCHER ARTHUR C | Officer | Sale | 17,313 | $1,758,189 |
| 2025-12-01 | BUTCHER ARTHUR C | Officer | Option Exercise | 17,313 | $429,491 |
| 2025-11-28 | O'SULLIVAN MIRIAM | Officer | Gift | 260 | - |
| 2025-11-14 | FITZGERALD JOSEPH MICHAEL | Officer | Gift | 10,300 | - |
| 2025-11-06 | ZANE ELLEN M | Director | Sale | 12,891 | $1,266,978 |
| 2025-11-03 | FITZGERALD JOSEPH MICHAEL | Officer | Sale | 50,000 | $4,973,338 |
| 2025-11-03 | FITZGERALD JOSEPH MICHAEL | Officer | Option Exercise | 50,000 | $1,307,500 |
| 2025-10-30 | MAHONEY MICHAEL F | Chief Executive Officer | Gift | 149,992 | - |
| 2025-10-28 | ZANE ELLEN M | Director | Sale | 12,891 | $1,306,900 |
| 2025-10-01 | FITZGERALD JOSEPH MICHAEL | Officer | Sale | 50,000 | $4,923,327 |
| 2025-10-01 | FITZGERALD JOSEPH MICHAEL | Officer | Option Exercise | 50,000 | $1,307,500 |
| 2025-09-02 | FITZGERALD JOSEPH MICHAEL | Officer | Sale | 50,000 | $5,271,416 |
| 2025-09-02 | FITZGERALD JOSEPH MICHAEL | Officer | Option Exercise | 50,000 | $1,307,500 |
| 2025-08-01 | LUDWIG EDWARD J. | Director | Gift | 500 | - |
| 2025-08-01 | FITZGERALD JOSEPH MICHAEL | Officer | Sale | 50,000 | $5,231,670 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
32 analysts
Oppenheimer
2026-01-16
Outperform
Outperform
Truist Securities
2025-12-18
Buy
Buy
Canaccord Genuity
2025-12-17
Buy
Buy
RBC Capital
2025-12-17
Outperform
Outperform
BTIG
2025-11-21
Buy
Buy
UBS
2025-10-23
Buy
Buy
Truist Securities
2025-10-23
Buy
Buy
Wells Fargo
2025-10-23
Overweight
Overweight
Morgan Stanley
2025-10-23
Overweight
Overweight
Canaccord Genuity
2025-10-23
Buy
Buy
Past News Coverage
Recent headlines mentioning BSX from our newsroom.
Newest → oldest
No matching news yet.